环林E-CDK2激酶活性对细胞定点的依赖性
1La Jolla Cancer Research Foundation, Cancer Center, CA 92037, USA.
Science (New York, N.Y.)
|January 26, 1996
概括
大多数非恶性细胞需要附着用于生长,在癌症中失去的依赖. 这项研究表明,对于细胞循环进展至关重要的环林E-CDK2复合体活性在悬浮细胞中被抑制,这可能解释了结依赖.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 非恶性细胞表现出结依赖性,需要基质附着才能生长和存活.
- 瘤转化导致这种关键定依赖的丧失.
- 细胞周期的G1-S转换是由关键蛋白质复合体调节的.
研究的目的:
- 研究环林E-CDK2复合体在依赖结的细胞生长中的作用.
- 确定瘤转化如何影响与细胞附着相关的环林E-CDK2活性.
- 为了阐明基底定依赖的分子机制.
主要方法:
- 人体纤维细胞的细胞培养在附着和悬浮状态.
- 在细胞周期期间分析环林E-CDK2复合物的活性.
- 评估CDK2抑制剂表达和CDK2酸化状态.
主要成果:
- 循环E-CDK2复合体激活发生在附着纤维细胞的G1阶段晚期,但在悬浮细胞中没有.
- 转变的纤维细胞显示了构成性环林E-CDK2复合物的活性,而不论附着.
- 悬浮细胞表现出增加的CDK2抑制剂和减少的CDK2酸化在threonine-160.
结论:
- 在悬浮细胞中抑制环林E-CDK2活性是定依赖的关键因素.
- 调节环林E-CDK2活性对于正常细胞生长控制至关重要.
- 了解这些机制可能会为癌症的发展和治疗策略提供见解.
更多相关视频
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
相关概念视频
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...